Van ECK Associates Corp Has $531,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Van ECK Associates Corp lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,110 shares of the biopharmaceutical company’s stock after selling 506 shares during the quarter. Van ECK Associates Corp’s holdings in Halozyme Therapeutics were worth $531,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. CWM LLC boosted its position in shares of Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 668 shares in the last quarter. Creative Planning increased its stake in Halozyme Therapeutics by 25.6% in the third quarter. Creative Planning now owns 46,834 shares of the biopharmaceutical company’s stock valued at $2,681,000 after purchasing an additional 9,543 shares in the last quarter. Raymond James & Associates increased its stake in Halozyme Therapeutics by 87.1% in the third quarter. Raymond James & Associates now owns 273,591 shares of the biopharmaceutical company’s stock valued at $15,660,000 after purchasing an additional 127,330 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of Halozyme Therapeutics by 6.2% in the third quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company’s stock valued at $1,383,000 after buying an additional 1,410 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in shares of Halozyme Therapeutics by 5,623.9% in the third quarter. International Assets Investment Management LLC now owns 36,576 shares of the biopharmaceutical company’s stock valued at $20,940,000 after buying an additional 35,937 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Stock Up 0.5 %

Shares of Halozyme Therapeutics stock opened at $57.75 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The stock has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.84, a P/E/G ratio of 0.42 and a beta of 1.25. The company’s 50 day moving average price is $53.46 and its 200-day moving average price is $54.64.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.